Enabling patient PRPs

Mercator strikes two deals to optimize its peptide-receptor pairs in cancer

After securing exclusive rights to an in vivo, patient-based screening platform for cancer-specific peptide-receptor pairs, Mercator Therapeutics Inc. needed a source of optimized peptides and antibodies. A pair of deals this month gives the biotech access to antibodies for targeting the receptors, and peptides for delivering toxins to tumors.

Mercator was founded in 2010 to commercialize the work of Renata Pasqualini and Wadih Arap, two researchers from the University of Texas M.D. Anderson Cancer Center who have spent more than a decade developing patient-based

Read the full 833 word article

How to gain access

Continue reading with a
two-week free trial.